Quantitative imaging in cancer clinical trials

Clinical Cancer Research

Volumn 22, Issue 2, 2016, Pages 284-290

  Yankeelov, Thomas E ^a   Mankoff, David A ^b   Schwartz, Lawrence H ^c   Lieberman, Frank S ^d   Buatti, John M ^e   Mountz, James M ^d   Erickson, Bradley J ^f   Fennessy, Fiona M M ^g   Huang, Wei ^h   Kalpathy Cramer, Jayashree ⁱ   L Wahl, Richard ^j   Linden, Hannah M ^k   Kinahan, Paul E ^l   Zhao, Binsheng ^c   Hylton, Nola M ^m   Gillies, Robert J ⁿ   Clarke, Laurence ^o   Nordstrom, Robert ^o   Rubin, Daniel L ^p  

^a VANDERBILT UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f MAYO CLINIC   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF WASHINGTON   (United States)

^l UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^o NATIONAL CANCER INSTITUTE   (United States)

^p STANFORD UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; FLUORODEOXYGLUCOSE F 18;

CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; HUMAN; IMAGE ANALYSIS; MEDICAL AUDIT; MOLECULARLY TARGETED THERAPY; PERFUSION WEIGHTED IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY CONTROL; QUANTITATIVE ANALYSIS; REVIEW; EVALUATION STUDY; MOLECULAR IMAGING; NEOPLASMS; PATHOLOGY; PROCEDURES;

CLINICAL TRIALS AS TOPIC; EVALUATION STUDIES AS TOPIC; HUMANS; MOLECULAR IMAGING; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84958750599     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-3336     Document Type: Review

References (35)

1. PiessevauxH, Buyse M, Schlichting M, Van Cutsem E, Bokemeyer C, Heeger S, et al. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2013;31:3764-75.
2. Zhao B, Oxnard GR, Moskowitz CS, Kris MG, Pao W, Guo P, et al. A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development. Clin Cancer Res 2010;16:4647-53.
3. Jain RK, Lee JJ, Ng C, Hong D, Gong J, Naing A, et al. Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol 2012;30:2684-90.
4. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
5. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963-72.
6. Vansteenkiste J, Fischer BM, Dooms C, Mortensen J. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: Systematic review. Lancet Oncol 2004;5:531-40.
7. Teng FF, Meng X, Sun XD, Yu JM. New strategy for monitoring targeted therapy: Molecular imaging. Int J Nanomedicine 2013;8:3703-13.
8. Mileshkin L, Hicks RJ, Hughes BG, Mitchell PL, Charu V, Gitlitz BJ, et al. Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib. Clin Cancer Res 2011;17:3304-15.
9. Zhao B, Schwartz LH,Moskowitz CS,Ginsberg MS, Rizvi NA, Kris MG. Lung cancer: Computerized quantification of tumor response-initial results. Radiology 2006;241:892-8.
10. Sohn HJ, Yang YJ, Ryu JS, Oh SJ, Im KC, Moon DH, et al. [18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung. Clin Cancer Res 2008;14:7423-9.
11. Yankeelov TE, Gore JC. Dynamic contrast enhanced magnetic resonance imaging in oncology: Theory, data acquisition, analysis, and examples. Curr Med Imaging Rev 2009;3:91-107.
12. Anderson AW, Xie J, Pizzonia J, Bronen RA, Spencer DD, Gore JC. Effects of cell volume fraction changes on apparent diffusion in human cells. Magn Reson Imaging 2000;18:689-695.
13. Van Den Abbeele AD. The Lessons of GIST-PET and PET/CT: A new paradigm for imaging. Oncologist 2008;13 Suppl 2:8-13.
14. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009;50 Suppl 1:122S-50S.
15. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with F-18-FLT and positron emission tomography. Nat Med 1998;4:1334-6.
16. Kostakoglu L,Duan F, Idowu MO,Jolles PR, BearHD,Muzi M, et al. Phase II study of 30-deoxy-30-18F fluorothymidine PET/CT (FLT-PET) in the assessment of early response in locallyadvanced breast cancer (LABC):preliminary results of ACRIN 6688. J Clin Oncol 32:5s, 2014 (suppl; abstr 526).
17. Gillies RJ, Verduzco D, Gatenby RA. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer 2012;12: 487-93.
18. Gatenby RA, GroveO, Gillies R J. Quantitative imaging in cancer evolution and ecology. Radiology 2013;269:8-14.
19. Yankeelov TE, Atuegwu N, Hormuth D, Weis JA, Barnes SL, Miga MI, et al. Clinically relevant modeling of tumor growth and treatment response. Sci Transl Med 2013;5:187ps9.
20. Meet Phannie, NIST's Standard Phantom' for Calibrating MRI Machines [about 3 screens] [cited 2015 Jul 24]. Available from: Http://www.nist.gov/pml/electromagnetics/phannie-051110.cfm.
21. Malyarenko D, Galb-an CJ, Londy FJ, Meyer CR, Johnson TD, Rehemtulla A, et al. Multi-system repeatability and reproducibility of apparent diffusion coefficient measurement using an ice-water phantom. J Magn Reson Imaging 2013;37:1238-46.
22. Standards for x-ray computed tomography [about 2 screens] [cited 2015 Jul 24]. Available from: Http://www.nist.gov/pml/div685/grp03/ctstandards. cfm.
23. Zimmerman BE, Pibida L, King LE, Bergeron DE, Cessna JT, Mille MM. Development of a calibration methodology for large-volume, solid 68Ge phantoms for traceable measurements in positron emission tomography. Appl Radiat Isot 2014;87:5-9.
24. Doot RK, Pierce LA II, Byrd D, Elston B, Allberg KC, Kinahan PE. Biases in multicenter longitudinal PET standardized uptake value measurements. Transl Oncol 2014;7:48-54.
25. Fahey FH, Kinahan PE, Doot RK, Kocak M, Thurston H, Poussaint TY. PET phantom: Variability in PET quantitation within amulticenter consortium. Med Phys 2010;37:3660-6.
26. Mountz JM, Yankeelov TE, Rubin DL, Buatti JM, Erikson BJ, Fennessy FM, et al. A letter to cancer center directors: Progress in quantitative imaging as a means to predict and/ormeasure tumor response in cancer therapy trials. J Clin Oncol 2014;32:2115-6.
27. Gerstner ER, Zhang Z, Fink JR, Muzi M, Hanna L, Greco E, et al. ACRIN 6684: Assessment of tumor hypoxia in newly diagnosed GBMusing FMISO PET and MRI. J Clin Oncol 33, 2015 (suppl; abstr 2024).
28. Erickson BJ, Pan T, Marcus DS; CTSA Imaging Informatics Project Group. Whitepapers on imaging infrastructure for research: Part 1: General workflow considerations. J Digit Imaging 2012;25:449-53.
29. Pan T, Erickson BJ, Marcus DS; CTSA Imaging Informatics Project Group. Whitepapers on imaging infrastructure for research part three: Security and privacy. J Digit Imaging 2012; 25:692-702.
30. CTP-The RSNA Clinical Trial Processor [about 100 screens] [cited 2015 Jul 24]. Available from: Http://mircwiki.rsna.org/index.php?titleCTPThe- RSNA-Clinical-Trial-Processor.
31. Aryanto KY, Broekema A, Langenhuysen RG, Oudkerk M, Van Ooijen PM. A web-based institutional DICOM distribution system with the integration of the Clinical Trial Processor (CTP). J Med Syst 2015; 39:45.
32. The DICOM Standard 2015 [about 2 screens] [cited 2015 Jul 24]. Available from: Http://medical.nema.org/standard.html.
33. Mankoff DA, Pryma DA, Clark AS. Molecular imaging biomarkers for oncology clinical trials. J Nucl Med 2014;55:525-8.
34. Channin DS, Mongkolwat P, Kleper V, Rubin DL. The annotation and image mark-up project. Radiology 2009;253:590-2.
35. Rubin DL, Willrett D, O'Connor MJ, Hage C, Kurtz C, Moreira DA. Automated tracking of quantitative assessments of tumor burden in clinical trials. Transl Oncol 2014;7:23-35.